Page 5,750«..1020..5,7495,7505,7515,752..5,7605,770..»

JSCM publishes issue on NIDRR-funded project on practice-based evidence in SCI rehabilitation

Posted: Published on February 6th, 2013

Public release date: 5-Feb-2013 [ | E-mail | Share ] Contact: Carolann Murphy cmurphy@kesslerfoundation.org 973-324-8382 Kessler Foundation West Orange, NJ. February 4, 2013. The final phase of the SCIRehab Project (Phase 3) was published in the November 2012 issue of the Journal of Spinal Cord Medicine (JSCM). Nine papers comprised the Special Issue: Relationship of Inpatient Rehabilitation Interventions to Outcomes Following Spinal Cord Injury. Guest editors: J. Scott Richards, Gale Whiteneck, Daniel Lammertse, Marcel Dijkers, and Julie Gassaway. Key article available for free download via ingentaconnect.com: Whiteneck G, Gassaway J. The SCIRehab Project: What rehabilitation interventions are most strongly associated with positive outcomes after spinal cord injury? Journal of Spinal Cord Medicine 2012;35(6): 482-483. The SCIRehab Project Phase 1 and Phase 2 articles were published in JSCM in June 2009 and March 2011, respectively. The Project was funded by the National Institute on Disability and Rehabilitation, Research Office of Rehabilitative Services, US Department of Education, to Craig Hospital (H133A060103 and H133N060005), The Mount Sinai School of Medicine (H133N060027), the National Rehabilitation Hospital (H133N060028), Rehabilitation Institute of Chicago (H133N060014) and to Shepherd Center (H133N060009), and Carolinas Rehabilitation. The SCIRehab Project used practice-based evidence research methodology to investigate inpatient rehabilitation practices for … Continue reading

Posted in Spinal Cord Injury Treatment | Comments Off on JSCM publishes issue on NIDRR-funded project on practice-based evidence in SCI rehabilitation

Telemedicine Helps Parkinson's Patients

Posted: Published on February 6th, 2013

SALISBURY, Md. - You may not be able to tell by looking at him, but Art Cooley knows Parkinson's all too well. He tells WMDT "in 2008/2009 I began to exhibit symptoms and after going to the doctor up to Johns Hopkins resources, they confirmed that I had Parkinson's disease." Considered a neurological disorder, Parkinson's can be treated by neurologists, but it can take a doctor trained as a movement specialist to provide a proper diagnosis. A recent study estimates as many as 7,000 people are living with this disease on Delmarva, but there aren't any movement specialists on the peninsula. This has brought the Lower Shore Parkinson's Support Group, the MAC center, and Johns Hopkins to work together to provide a new way to help patients diagnose the debilitating disease. Dr. Renee Fredericksen is the Special Projects Director for MAC Inc. in Salisbury. There, she runs the Caregiver Resource Center where a new Telemedicine program will start mid February. "Telemedicine enables us to use telephone lines and computer access to bring doctors with specialties and other specialist in the world right into your home," says Fredericksen. While the consultations aren't available in the home just yet, Fredericksen says that … Continue reading

Posted in Parkinson's Treatment | Comments Off on Telemedicine Helps Parkinson's Patients

Teva begins Phase IV Azilect mild cognitive impairment trial

Posted: Published on February 6th, 2013

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) today announced that it has enrolled the first patient in the Phase IV clinical trial of Azilect. The study will evaluate the cognitive function in adults with mild cognitive impairment in Parkinson's disease. The study will evaluate the effect of Azilect on cognitive function in adults with mild cognitive impairment in Parkinson's, as assessed by the Scales for Outcomes of Parkinson's Disease-Cognition after 24 weeks of treatment. The study includes 170 patients at 30 sites in the US. Cognitive impairment in Parkinson's disease is a major cause of disability and increased care partner burden, said Dr. Robert A. Hauser, director of the Parkinson's Disease & Movement Disorders Center at the University of South Florida, the co-primary investigator of the study. As currently there are no available treatments for cognitive impairment in Parkinson's disease, any therapy that may demonstrate benefit would be welcomed for this significant unmet need." Teva chief scientific officer and president Global R&D Dr. Michael Hayden said, Mild cognitive impairment in Parkinson's disease is common in non-demented Parkinson's patients and is associated with increasing age, disease duration and disease severity." Published by Globes [online], Israel business news - http://www.globes-online.com - … Continue reading

Posted in Parkinson's Treatment | Comments Off on Teva begins Phase IV Azilect mild cognitive impairment trial

Pioneering Brain Surgeon Brings Exciting New Option to Parkinson's Disease Patients

Posted: Published on February 6th, 2013

LOS ANGELES, Feb. 5, 2013 /PRNewswire/ --One of the first known surgeons to offer Deep Brain Stimulation (DBS) as an outpatient treatment, Christopher Duma, MD, FACS, is bringing a new option and hope to the estimated 60,000 Americans diagnosed with Parkinson's Disease every year. The pioneering brain surgeon, who has successfully controlled tremors in thousands of movement disorder patients, is now performing his minimally invasive implantations at DISC Surgery Center at Newport Beach. Patients can literally walk in, have the surgery and be home in time for dinner, with their quality of life improved exponentially. DISC's outpatient setting also means individualized attention, fewer complications and a dramatically reduced risk of infection. With a marked improvement in 90% of cases, DBS is delivered by an implant that conducts a fine electrical impulse to particular parts of the brain. Wires are implanted in the brain and are connected to a device under the skin near the collar bone that regulates a continuous current. Despite being called 'stimulation' DBS actually shuts down areas of the brain that are causing the symptoms of Parkinson's Disease. Unlike medications that tend to have negative side effects over time, DBS has a positive record for minimal side … Continue reading

Posted in Parkinson's Treatment | Comments Off on Pioneering Brain Surgeon Brings Exciting New Option to Parkinson's Disease Patients

Stillwater couple getting Parkinson's patients into treatment studies

Posted: Published on February 6th, 2013

In July 2009, during one of their daily dog walks, Libbe Erickson noticed that her husband, Kim, was dragging his feet. A year later, Kim, a pilot for Delta Airlines, was on a layover in Honolulu. He got up one morning, went into the bathroom of his hotel and started shaving. He looked into the mirror and saw that his right hand was shaking. "It wasn't from being tired or from working out," Kim Erickson said. "I had just woken up; I was fairly rested." When he got home, Erickson went to see a neurologist in Stillwater. The diagnosis: Parkinson's disease, a disorder of the brain that leads to tremors as well as trouble with walking, movement and coordination. There is no known cure, but the Ericksons, who live in Grant, are working to change that. The couple became research advocates for the Parkinson's Disease Foundation and are working to get other Parkinson's patients involved in studies that could lead to new drugs. "The only way we're going to make advances is if people living with Parkinson's participate in research studies," Kim Erickson said. "The real hindrance with Parkinson's research right now is the number of study participants is so … Continue reading

Posted in Parkinson's Treatment | Comments Off on Stillwater couple getting Parkinson's patients into treatment studies

Aqueduct: Dominguez begins rehabilitation program for brain injury

Posted: Published on February 6th, 2013

Email Barbara D. Livingston It is uncertain how long Ramon Dominguez will have to remain at his rehabilitation facility. Jockey Ramon Dominguez has begun a brain injury rehabilitation program at a hospital in White Plains, N.Y., as he continues to recover from a fractured skull he suffered in a spill at Aqueduct last month. Last Wednesday, Dominguez was transferred from New York-Presbyterian Hospital/Weill Cornell Medical Center in Manhattan to the Burke Rehabilitation Hospital. It is uncertain how long he will have to remain at Burke. "Ramon continues to do well and is improving every day," Sharon Dominguez, Ramon's wife, said in a press release issued through the New York Racing Association. "He was transferred to Burke on Wednesday, completed initial evaluations on Thursday, and started a brain injury rehabilitation program on Friday. "As Ramon takes the next steps in his treatment, he and I would like to thank everyone again for the continued support and prayers." Dominguez added. "Although his injury will take time to heal, Ramon is on the road to a full recovery." Dominguez, 36, was injured in a spill at Aqueduct on Jan. 18 when the horse he was riding, Convocation, clipped heels with a horse in … Continue reading

Posted in Brain Injury Treatment | Comments Off on Aqueduct: Dominguez begins rehabilitation program for brain injury

High risk of cardiovascular diseases amongst Swedish-born and immigrant MS patients

Posted: Published on February 6th, 2013

Feb. 4, 2013 A new study from Karolinska Institutet in Sweden shows that patients with multiple sclerosis (MS) run a high risk of heart attack, stroke and heart failure, regardless of migration background. According to Dr Tahereh Moradi, principal investigator, the study is the first in the world to examine the risk of cardiovascular diseases in male and female MS patients with both non-immigrant and immigrant backgrounds. MS is a chronic inflammatory disease that breaks down the central nervous system, and is the most common neurological cause of disability amongst young people. The study now published in the scientific periodical Multiple Sclerosis Journal examined over 8,000 MS patients between the years 1987 and 2009. "It turns out that MS patients run a 85 per cent higher risk of myocardial infarction, a 70 per cent higher risk of stroke, and a 100 per cent higher risk of heart failure, results that are consistent in both young and elderly patients, and patients born in and outside Sweden, with the effect being particularly noticeable for women," says principal investigator Dr Tahereh Moradi, Associate Professor at Karolinska Institutet's Institute of Environmental Medicine. With MS striking two in every 10,000 people, primarily women, every year, … Continue reading

Posted in MS Treatment | Comments Off on High risk of cardiovascular diseases amongst Swedish-born and immigrant MS patients

One in Three Children with MS has Cognitive Impairment

Posted: Published on February 6th, 2013

Stony Brook-led Study in Journal of Child Neurology is largest ever, includes data from all Pediatric MS Centers of Excellence Watch: One in Three Children with Multiple Sclerosis has Cognitive Impairment Newswise STONY BROOK, N.Y., February 5, 2013 Data from the largest multicenter study accessing cognitive functioning in children with multiple sclerosis (MS) reveals that one-third of these patients have cognitive impairment, according to a research paper published in the Journal of Child Neurology. Led by Lauren B. Krupp, MD, Director of the Lourie Center for Pediatric Multiple Sclerosis at Stony Brook Long Island Childrens Hospital, the study indicates that patients experience a range of problems related to cognition. In Cognitive Impairment Occurs in Children and Adolescents with Multiple Sclerosis: Results from a United States Network, Dr. Krupp and colleagues from Stony Brook and five other national Pediatric MS Centers of Excellence measured the cognitive functioning of 187 children and adolescents with MS, and 44 who experienced their first neurologic episode (clinically isolated syndrome) indicative of MS. They found that 35 percent of the patients with MS and 18 percent of those with clinically isolated syndrome met criteria for cognitive impairment. All patients were under age 18 with an average … Continue reading

Posted in MS Treatment | Comments Off on One in Three Children with MS has Cognitive Impairment

Elan to raise USD3.25bn for buy-outs

Posted: Published on February 6th, 2013

Wednesday, February 06 11:44:29 Irish drugmaker Elan is raising more than $3.25 billion by selling its interests in its main drug and will splash out most of the proceeds on acquisitions, effectively reinventing itself as a company. Under a deal announced today, Elan's partner Biogen Idec will take full ownership of blockbuster multiple sclerosis (MS) treatment Tysabri and will make an upfront payment to the Irish group plus royalties on future sales. While the deal gives Elan scope to return some cash to shareholders as well as strategic flexibility to buy new assets, it leaves its future shape unclear since Tysabri was by far its most important product, responsible for almost all its revenue. Elan has already spoken to several companies about potential deals and can move quickly once the sale its completed, Chief Executive Kelly Martin told Reuters. "You can do a lot of things with $3 billion, you can buy companies, molecules, you can partner, you can share risk. The world is our oyster," Martin said in a telephone interview. "We are not necessarily restricting ourselves to one therapeutic area or one type of clinical asset. We will not be restricted to our past, which was by and … Continue reading

Posted in MS Treatment | Comments Off on Elan to raise USD3.25bn for buy-outs

UPDATE 4-Elan seeks acquisitions after $3.25 bln Biogen deal

Posted: Published on February 6th, 2013

* Elan agrees to cede control of Tysabri to U.S. partner * Elan has already spoken to companies about potential deals * Biogen says deal a natural step, will add to 2013 earnings * Irish company's shares rise 8 pct, highest since November (Xetra: A0Z24E - news) By Padraic Halpin DUBLIN, Feb 6 (Reuters) - Irish drugmaker Elan will raise more than $3.25 billion by selling its interests in its main drug to partner Biogen Idec (NasdaqGS: BIIB - news) and effectively reinvent itself by splashing most of the cash on acquisitions. Under a deal announced on Wednesday, Massachusetts-based Biogen will take full ownership of blockbuster multiple sclerosis (MS) treatment Tysabri and will make an upfront payment to the Irish group plus royalties on future sales. While the deal gives Elan scope to return some cash to shareholders as well as strategic flexibility to buy new assets, it leaves its future shape unclear since Tysabri was by far its most important product, responsible for almost all its revenue. Elan has already spoken to several companies about potential deals and can move quickly over the next 12-18 months once the sale is completed, Chief Executive Kelly Martin told Reuters. "You can … Continue reading

Posted in MS Treatment | Comments Off on UPDATE 4-Elan seeks acquisitions after $3.25 bln Biogen deal

Page 5,750«..1020..5,7495,7505,7515,752..5,7605,770..»